BDA is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Past gains are not a representative of future gains. Co-Diagnostics is a client of BDA International. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the BDA may at times hold a position in the company covered within the article. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this analysis. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. Parties interested in learning more about the relationship between BDA and CODX may do so via the contact information at the bottom of this release. BDA International accepts sole responsibility for the content and distribution of the foregoing release, which does not contain any previously unpublished or non-public information. BDA International has received no direct compensation related to this release but its principles hold shares of client companies in our personal portfolios, including CODX. In particular, we provide and are compensated for service packages that include strategic action plans and investor/market perception studies to help entities improve communication with customers and investors, and to increase their visibility. With additional tests on the way, including HIV and a multiplexed panel for blood-bank screening, and ambitions for global expansion, the test approvals and impending revenue are major-and welcome-steps forward for a company that has devoted so much time to a healthcare market that the company CEO has described as soon to become the largest on the planet.ĭisclosure: Co-Diagnostics Inc is a client of BDA International.īDA International is an independent global Investor Relations firm offering a wide range of IR-related analysis, research and advisory services. The news also announced that distributors are already taking pre-orders for the newly approved diagnostics. Today’s release indicates that the wait between inauguration and production is due to the rigorous inspection process of the tests and plant following its completion, marking this as the first time CoSara has been able manufacture and sell tests from its facility. That means that this news is essentially equivalent to a company receiving FDA approval for five diagnostics at the same time-but for a population roughly 4 times larger than the US, and one that is heavily afflicted by all of the diseases in question.Ĭo-Diagnostics announced the inauguration of the JV manufacturing plant earlier this year, one of the first of its kind in India. Why is this important? The Indian Central Drug Standard Control Organization (or “CDSCO”) is the regulatory body responsible for approving pharmaceuticals and medical devices for use in the Indian healthcare market, serving a parallel function as the Food and Drug Administration in the United States, making CDSCO approval in India analogous to FDA approval in the US. The approved tests include those for tuberculosis, malaria, hepatitis B, hepatitis C, and human papillomavirus. (Nasdaq: CODX), a biotech company with a patented platform for the development of molecular diagnostic tests, released what could arguably be the most significant news in its history earlier today with the announcement that Indian regulators have approved five in vitro diagnostic assays to be manufactured and sold by CoSara Diagnostics Pvt Ltd., the company’s joint venture for manufacturing in India. 03, 2019 (GLOBE NEWSWIRE) - Co-Diagnostics, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |